News | September 09, 2014

Claret Medical Secures Funds to Advance the Field of Celebral Protection

Proceeds will fund randomized, Pivotal SENTINEL Trial to study how cerebral protection may reduce the incidence of stroke in transcatheter aortic valve replacement

Claret Medical Sentinel Cerebral Protection System Celebral Protection

September 9, 2014 — Claret Medical Inc. vascular and cardiac surgery procedures, announced that it has entered into an agreement for up to $18 million in a Series B financing. The Series B round was led by Santé Ventures, a prominent healthcare-focused venture capital firm with $260 million in capital under management, with participation from Lightstone Ventures, a leading venture capital firm with $172 million under management. Easton Capital also joined the round. James Eadie from Santé Ventures and Hank Plain from Lightstone Ventures will be joining the company’s Board of Directors.

Proceeds will be used primarily to complete the U.S. pivotal clinical trial of the company’s Sentinel Cerebral Protection System (CPS) for embolic protection during transcatheter aortic valve replacement (TAVR), which received Investigational Device Exemption (IDE) approval earlier this year.

The Sentinel CPS is the only filter-based system on the market that both captures and removes embolic debris released during TAVR procedures that could otherwise be a source of peri-procedural stroke.  The system has been used in more than 800 procedures worldwide to date.

“Many consider the stroke rate in TAVR concerning, especially as clinicians look to bring the benefits of TAVR to lower risk and younger patients,” said Azin Parhizgar, Ph.D., president and CEO of Claret Medical. “The proceeds of this financing round will enable Claret Medical to conduct the SENTINEL pivotal trial, which we expect to confirm the therapeutic importance of embolic debris capture and removal during TAVR. This same approach has long been established in carotid stenting procedures.”

“The SENTINEL trial will evaluate the role of the Sentinel CPS in reducing the number and size of new ischemic lesions in the brain and their potential impact on patients’ neurocognitive function,” said Martin Leon, M.D., director of the Center for Interventional Vascular Therapy at Columbia University Medical Center in New York and chair of the trial’s Clinical Steering Committee. “By doing so, the trial will help define the field of cerebral protection during TAVR in order to pave the way for safer TAVR procedures.”

The company is also embarking upon two other studies of structural heart procedures that could benefit from the use of the Sentinel CPS in reducing cerebrovascular events during complex surgical and transcatheter procedures.

For more information:

Related Content

Videos | Heart Valve Technology | March 15, 2018
Insights from the STS/ACC TVT Transcatheter Valve Registry, presented at the American College of Cardiology (ACC) 201
CoreValve TAVR System Shows Strong Long-Term Performance in Clinical Trials
News | Heart Valve Technology | March 12, 2018
Medtronic plc unveiled outcomes from the CoreValve U.S. Pivotal Extreme Risk Study and the real-world NOTION trial (...
The U.S. Food and Drug Administration expanded the approval of a heart valve to include a size small enough to be used in newborn pediatric patients to treat heart defects.
News | Heart Valve Technology | March 07, 2018
The U.S. Food and Drug Administration expanded the approval of a heart valve to include a size small enough to be used...
Videos | Heart Valve Technology | March 02, 2018
Sammy Elmariah, M.D., MPH, interventional structural heart disease, Massachusetts General Hospital, discusses the pro
Boston Scientific Projects 2019 Launch for Lotus Edge Aortic Valve System
News | Heart Valve Technology | February 23, 2018
February 23, 2018 — Boston Scientific announced In November 2017 a delay to timelines for commercialization of the Lo
Gate Bioprosthesis Used in Canada's First Transcatheter Valve Replacement for Tricuspid Regurgitation
News | Heart Valve Technology | February 22, 2018
NaviGate Cardiac Structures Inc. (NCSI)announced that on Feb. 2, 2018, its catheter-guided Gate valved-stent...
Edwards Lifesciences Centera self expanding transcatheter (TAVR) valve has been approved with CE mark for use in Europe.
Feature | Heart Valve Technology | February 15, 2018
February 15, 2018 — Edwards Lifesciences Corp.
Boston Scientific Enters Investment and Acquisition Option Agreement With Millipede
News | Heart Valve Technology | January 24, 2018
Boston Scientific Corp. announced it has closed an investment and entered into an acquisition option agreement with...
Edwards LifeSciences Recalls Sapien 3 Certitude Delivery System
News | Heart Valve Technology | January 11, 2018
The U.S. Food and Drug Administration (FDA) announced that Edwards LifeSciences is recalling its Certitude Delivery...
Videos | Heart Valve Technology | January 04, 2018
Adam Greenbaum, M.D., co-director, Center for Structural Heart Disease, Henry Ford Hospital, Detroit, explains how hi
Overlay Init